Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anidulafungin and BDG Biomarkers in ICU Invasive Candidiasis
NCT01734525Phase 4Completed
- Sponsor
- Federal University of Rio de Janeiro
- Start
- Nov 2012
- Primary completion
- Dec 2013
- Modality
- Small Molecules, Cyclic Peptides
- Countries
- 1
01
Overview
Phase 4, open-label trial of anidulafungin in candidemia and invasive candidiasis, sponsored by Federal University of Rio de Janeiro. Primary endpoint: Occurrence of Candidemia in Patients With Negative 1,3 Beta-D-glucan Who Discontinue Anidulafungin at 30 days. Started Nov 2012; status: completed.
02
Drugs
anidulafungin
03
Conditions
candidemiainvasive candidiasis
Beyond the preview
Go deeper on NCT01734525.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01734525.